AstraZeneca Investor Day Presentation Deck

FELLESSERTER Annual WW Incidence (000s) GI tumours are the next pillar for AstraZeneca in oncology complementing strong presence in lung & breast 7000 Annual worldwide incidence by cancer type Existing AstraZeneca presence ENHERTU fam-trastuzumab deruxtecan-nxki 20 mg/mL INJECTION FOR INTRAVENOUS USE Lynparza olaparib tabiateg FASLODEX fulvestrant breast SIMFINZIⓇ durvalumab the 50 mg TAGRISSO osimertinib lung Lynparza olaparib tatis omg Zoladex goserelin CALQUENCE (acalabrutinib) 100 mg capsules prostate leukaemia Lynparza olaparib ovarian pancreas oesophagus hepatobiliary gastric colorectal Levels of heterogenicity seen in Gl cancers shows the need for a varied arsenal of medicines across the GI cancer landscape GI Source: Globocan (Globocan 2020 Estimates of Incidence and Mortality Worldwide; GLOBOCAN Cancer Today, 2018). WW = worldwide; GI = gastrointestinal. Lynparza® olaparib ENHERTU fam-trastuzumab deruxtecan-mxki 20 ng/mL INJECTION FOR INTRAVENOUS USE

View entire presentation